UNICA IRIS Institutional Research Information System

CAOCCI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 195.069
NA - Nord America 12.052
AS - Asia 1.626
OC - Oceania 32
SA - Sud America 26
AF - Africa 24
Continente sconosciuto - Info sul continente non disponibili 11
Totale 208.840
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 191.674
US - Stati Uniti d'America 11.947
UA - Ucraina 1.125
CN - Cina 1.062
SE - Svezia 1.007
FI - Finlandia 339
GB - Regno Unito 330
DE - Germania 278
VN - Vietnam 173
FR - Francia 135
SG - Singapore 118
IN - India 103
CA - Canada 89
IE - Irlanda 33
IR - Iran 32
AU - Australia 28
RU - Federazione Russa 27
JP - Giappone 26
NL - Olanda 26
BE - Belgio 23
HK - Hong Kong 19
MY - Malesia 17
KR - Corea 16
MX - Messico 13
BR - Brasile 12
TR - Turchia 12
CH - Svizzera 11
EU - Europa 11
AT - Austria 10
EG - Egitto 10
BG - Bulgaria 9
PL - Polonia 9
IQ - Iraq 8
PK - Pakistan 7
CZ - Repubblica Ceca 5
ES - Italia 5
TN - Tunisia 5
AR - Argentina 4
CL - Cile 4
HU - Ungheria 4
ID - Indonesia 4
JO - Giordania 4
NZ - Nuova Zelanda 4
PE - Perù 4
RO - Romania 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
KE - Kenya 3
LT - Lituania 3
PA - Panama 3
PH - Filippine 3
SA - Arabia Saudita 3
BD - Bangladesh 2
GR - Grecia 2
HR - Croazia 2
LB - Libano 2
NO - Norvegia 2
TH - Thailandia 2
ZA - Sudafrica 2
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
EC - Ecuador 1
ET - Etiopia 1
GE - Georgia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
MZ - Mozambico 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 208.840
Salva come PNG Salva come JPEG
Città #
Cagliari 190.560
Fairfield 1.725
Woodbridge 1.325
Houston 855
Chandler 843
Ashburn 831
Nyköping 709
Wilmington 705
Seattle 690
Ann Arbor 689
Cambridge 618
Jacksonville 591
Boardman 304
New York 290
Beijing 247
Nanjing 213
Boston 198
Dong Ket 170
Helsinki 163
Dearborn 125
San Diego 115
Milan 93
Rome 85
Shanghai 84
Redwood City 67
Shenyang 63
Hebei 59
Nanchang 58
Menlo Park 57
Mountain View 55
Guangzhou 53
Toronto 50
Changsha 47
Norwalk 45
Atlanta 40
London 39
Tianjin 39
Verona 35
Washington 34
Orange 33
Jiaxing 30
Falls Church 29
Jinan 29
Pune 28
Phoenix 27
Sassari 25
Zhengzhou 23
Los Angeles 22
Auburn Hills 20
Brussels 20
Ningbo 17
Redmond 17
San Jose 16
Borås 15
Saint Petersburg 15
Sydney 15
Hangzhou 14
Hefei 14
Hong Kong 14
Quartu Sant'Elena 14
Palermo 12
Ahmedabad 11
Dublin 11
Naples 11
Quartu Sant'elena 10
San Mateo 10
Kunming 9
Messina 9
Oxford 9
Taizhou 9
Augusta 8
Bari 8
Rio de Janeiro 8
Singapore 8
Sofia 8
Tokyo 8
Andover 7
Chicago 7
Delhi 7
Hounslow 7
Kilburn 7
Kobe 7
Krefeld 7
Paris 7
Shenzhen 7
Turin 7
Amsterdam 6
Baghdad 6
Bologna 6
Florence 6
Kuala Lumpur 6
New Delhi 6
Sesto Fiorentino 6
Sestu 6
Trento 6
Bangalore 5
Borghetto di Borbera 5
Chengdu 5
Costa Mesa 5
Elmas 5
Totale 203.704
Salva come PNG Salva come JPEG
Nome #
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.044
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma 3.386
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.120
What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics 2.997
Comparison Between an Artificial Neural Network and Logistic Regression in Predicting Long Term Kidney Transplantation Outcome 2.938
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 2.893
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 2.885
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.804
Reassessing the approach to informed consent: The case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 2.737
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 2.703
Leucocyte classification for leukaemia detection using image processing techniques 2.613
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma 2.565
KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation 2.541
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients 2.408
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.390
A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes 2.339
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.208
Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia 2.120
Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib 2.100
Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma 1.929
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 1.894
Health related quality of life in patients with onco-hematological diseases 1.850
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 1.809
Role of human leukocyte antigen-G 14-base pair polymorphism in kidney transplantation outcomes 1.800
Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 1.767
null 1.759
Ruxolitinib therapy and telomere length in myelofibrosis 1.757
Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis 1.705
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.671
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.649
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.575
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 1.561
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.538
Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia 1.474
THE HLA-G 14-BP POLYMORPHISM IS AN INDEPENDENT GENETIC RISK MARKER OF LONG-TERM KIDNEY TRANSPLANTATION OUTCOME 1.466
Acute basophilic leukemia with U2AF1 mutation 1.455
T cell tyrosine phosphorylation response to transient redox stress 1.431
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis 1.427
The human leukocyte antigen-g 14-bp polymorphism is an independent genetic risk marker of long-term kidney transplantation outcome 1.419
null 1.419
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 1.405
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.366
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report 1.355
Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia 1.351
Systemic Mastocytosis with Associated Primary Myelofibrosis 1.328
Thresholds for clinical importance were defined for the EORTC CAT Core - an adaptive measure of core quality of life domains in oncology clinical practice and research 1.322
Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors 1.318
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation 1.292
Resolution of capillary leak syndrome by extracorporeal membrane oxygenation 1.279
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.278
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 1.267
Defibrotide in the COVID-19 coagulopathy: what is the timing? 1.240
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.238
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 1.224
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.222
Immunological deregulation in classic hodgkin lymphoma 1.199
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 1.176
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? 1.151
Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm 1.148
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.144
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 1.142
null 1.138
Rectal involvement in pre-early T acute lymphoblastic leukemia 1.134
null 1.128
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia 1.122
null 1.110
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: A multicentre, prospective, observational, cohort study 1.105
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes 1.088
null 1.048
Perls stain grade in bone marrow aspirate correlates with overall survival in low-risk myelodysplastic patients 1.036
null 1.034
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated donor hematopoietic stem cell transplantation in thalassemia patients 1.024
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation 1.018
White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy 999
null 984
Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research 982
The role of inhibitory KIR 2DL5 in the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma 977
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation: a crystal ball to foresee the future? 942
Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab 941
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis 939
Paroxysmal nocturnal hemoglobinuria: clinical expression and response to treatment are modified by a unique interaction with co-existing glucose 6-phosphate dehydrogenase deficiency 933
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? 922
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity 913
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index 911
null 904
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment 895
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? 893
null 890
Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease 873
Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH 868
Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment 842
Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone 817
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 814
Back to life -living, treating, managing myelofibrosis: the burden of illness for patients and their families. 800
Low-Dose Ponatinib Is A Good Option In Chronic Myeloid Leukemia Patients Intolerant To Previous Tkis 798
Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia 781
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes 778
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation: a crystal ball to foresee the future? 765
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 759
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice 756
Totale 149.252
Salva come PNG Salva come JPEG
Categoria #
all - tutte 269.602
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 269.602
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.101 0 0 0 0 0 0 0 0 0 588 640 873
2019/202036.762 2.177 1.000 356 1.075 12.682 8.820 4.774 1.487 1.048 911 954 1.478
2020/202156.948 1.709 2.254 2.752 13.090 10.912 6.431 5.338 3.686 1.243 4.278 3.109 2.146
2021/202217.322 1.674 1.367 820 915 1.235 1.281 835 875 1.405 2.021 2.587 2.307
2022/202322.185 1.654 2.475 2.451 1.687 2.012 2.372 961 2.724 1.364 1.400 2.052 1.033
2023/202420.872 1.275 1.050 1.468 1.954 2.229 4.706 3.680 1.828 1.345 1.337 0 0
Totale 209.812